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Abstract
Purpose α-fetoprotein (AFP) and human chorionic gonadotro-
pin subunit beta (B-HCG) are informative serum biomarkers
for the primary diagnosis and follow-up of testicular germ cell
cancer (TGCC) patients. About 20% of TGCC patients with a
non-seminoma (NS) and about 80%with a seminoma (SE) are,
however, negative for these biomarkers. Embryonic stem cell
microRNAs (miRs) may serve as promising alternative serum
biomarkers. Here we investigated a retrospective series of se-
rum samples from selected TGCC patients who developed a
relapse in time to test the possible additional value of the
serum-based ampTSmiR test compared to the conventional
serum-based protein biomarkers for follow-up.
Methods We investigated 261 retrospective serum samples of
six selected fully evaluated TGCC patients with a proven re-
lapse using the ampTSmiR test for miR-371a-3p, miR-373-
3p, and miR-367-3p and compared the results to those of the
conventional protein biomarkers.
Results At primary diagnosis, elevated serum B-HCG,
AFP and LDH levels were found to be informative in
4/6, 3/6 and 3/6 patients, respectively. At primary diag-
nosis the levels of miR-371a-3p and miR-373-3p were
elevated in 4/4, and miR-367-3p in 3/4 patients. For
two cases no starting serum sample was available for
retrospective miR analysis. Residual disease (overlooked
by histopathological examination) was detected in one
case by miR-371a-3p only. The miR-371a-3p level was
increased in one patient two months before detection of
an intracranial metastasis. B-HCG was informative in 3/
4 and the ampTSmiR test in 4/4 patients with a relapse
or residual disease. None of the biomarkers were infor-
mative for the detection of residual mature teratoma.
Conclusions The ampTSmiR test is more sensitive than the
conventional TGCC protein biomarkers for the detection of
residual disease and relapse, excluding mature teratoma.
Keywords Testicular germ cell cancer . microRNA . Serum
biomarkers . B-HCG . AFP
1 Introduction
Although germ cell cancer (GCC) is rare in the general
population, it represents the most frequent malignancy in
young Caucasian males, predominantly of the testis, ac-
counting for 60% of all malignancies in these males be-
tween 20 and 40 years of age [1]. Its incidence is increas-
ing [2] and long-term effects of systemic treatment are
evident [3]. Therefore, efforts are being made to diagnose
this disease at an early stage. Clinically and histologically,
TGCC are divided into two main subtypes, seminoma (SE)
and non-seminoma (NS), both derived from pre-invasive
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germ cell neoplasia in situ (GCNIS) which, in turn, origi-
nates from a transformed primordial germ cell or gonocyte
[4, 5]. NS can be heterogeneous, consisting of the histo-
logic variants embryonal carcinoma (EC), yolk sac tumor
(YST), choriocarcinoma (CH) and teratoma (TE) [1, 4,
6–8]. Although the 5-year survival rate of TGCC patients
exceeds 96%, patients have a long term risk of developing
a second primary TGCC or of progression of the disease
[9]. Therefore, they undergo intensive and long-term fol-
low-up after initial diagnosis, including extensive physical
examination and monitoring of the levels of the conven-
tional serum protein markers B-HCG, AFP and to a lesser
extent LDH, due to its low specificity [10]. Serum bio-
marker positivity relates to the histology of the primary
(and possibly metastasized) tumor. As such, B-HCG is
predominantly related to the presence of a CH component
and AFP to a YST component, whereas they show little
sensitivity for the detection of SE and the NS stem cell
component EC. This explains why a substantial percentage
of TGCC patients, predominantly without CH and YST
components, can be serum biomarker negative at initial
diagnosis or become negative during follow-up, respec-
tively. In addition, false positive findings can be obtained,
in case of B-HCG due to other malignancies, chemothera-
py or marijuana use and in case of AFP due to chronic liver
disease, liver damage or liver cancer [11, 12]. Therefore,
there is a clinical need for biomarkers with a better sensi-
tivity, especially related to (pure) SE and EC, for primary
tumor or metastasis detection (reviewed in [13]). The ad-
vent of techniques such as microRNA (miR) profiling has
allowed the identification a number of small non-coding
RNAs specifically expressed in (T)GCC [14, 15]. In par-
ticular, it has been found that the expression of miR371a-
3p, miR-372-3p, miR-373-3p and the miR-302a-d/367-3p
cluster is characteristic for (T)GCC as well as embryonic
tissues, excluding fully somatic differentiated (TE) tissues.
These miRs have been reported to serve as circulating mo-
lecular serum biomarkers in patients with testicular and
intracranial GCC [14–20]. It has been found that miR-
371a-3p outperforms the other miRs in the detection of
primary GCCs, the reason of which is still unexplained
[18, 19, 21]. So far, most studies have focused on the value
of these biomarkers in primary diagnosis and during che-
motherapy [22], but not yet extensively during follow-up.
In the current proof-of-concept study, we examined the
levels of miR-371a-3p, miR-373-3p and miR-367-3p in
serum samples of a follow-up series of selected TGCC
patients ranging from the time of primary diagnosis to re-
lapse and complete remission. Our results confirm the
power of elevated serum miR-371a-3p, 373-3p and 367-
3p levels for primary TGCC diagnosis and show the effi-
cacy of the ampTSmiR test for TGCT relapse detection,
outperforming conventional serum biomarkers.
2 Materials and methods
2.1 Clinical samples
The study was approved by the institution’s Medical Ethical
Committee (MEC 02· 981 and CCR2041). We adhere to the
BCode for Proper Secondary Use of Human Tissue in
The Netherlands^ developed by the Dutch Federation of
Medical Scientific Societies (FMWV, version 2002, update
2011). Serum samples were collected between January 2000
and December 2008 in the Daniel den Hoed Cancer Center,
Erasmus MC and stored in liquid nitrogen or at −80 °C until
use. The patients were selected based on the number of avail-
able serum samples, as well as on the availability of clinical
follow-up data. Specifically, the presence of relapse and/or
residual disease was used for selection. Based on these
criteria, we included serum samples of one SE patient (stage
I) and five NS patients (one stage I; one stage I with a second
primary tumor stage IIA and three with stage IV disease). The
median age at primary diagnosis was 23.5 years, mean 26.8
(range 21–39). The sera were visually inspected for hemoly-
sis. One sample showedmoderate and 5 samples showedmild
hemolysis. No samples were excluded for analysis. Further
clinical details are listed in Supplementary Table 1.
2.2 miRNA purification, quantitative real-time PCR
(RT-qPCR) and interpretation
For the ampTSmiR test, miRNAs (miRs) were isolated from
50 μl serum using target specific anti-miR magnetic beads as
reported before [18]. In short, a MagMax™ Express-96 robot
with TaqMan® miRNA ABC Purification Kits panel A was
used to isolate miRs. A non-human spike-in ath-miR-159a
was added to the sera (0.2 μl of a 1 nM stock solution) for
quality control of targeted miR isolation and cDNA genera-
tion. In each cDNA synthesis experiment, four ten-fold dilu-
tion series of purified miR of the TCam-2 seminoma cell line
was included for quality control, qPCR efficiency and inter-
plate calibration. Purified miR was reverse transcribed to miR
specific cDNA using a TAQMAN MICRORNA RT KIT.
cDNA generation and quantification of miR levels were per-
formed using TaqMan Micro RNA assays for the analysis of
hsa-miR-371a-3p (002124), hsa-miR-373-3p (000561), hsa-
miR-367-3p (000555), ath-miR-159a (000338) and hsa-
miR-30b-5p (000602). To increase sensitivity and specificity,
a 13-cycle pre-amplification step was included. miR levels
were determined on a TaqMan 7500 Real-Time PCR system
(all apparatuses and kits: Thermo Fisher Scientific, Bleiswijk,
the Netherlands). For normalization, endogenous reference
miRmiR-30b-5p was used [14, 18, 22]. To determine whether
a sample is positive or negative, a threshold was calculated
using previously generated data [18]. This set included both
proven diseased (TGCC) as well as healthy males. Thresholds
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for positivity were calculated using the Youden index. This
resulted in a 89% sensitivity and a 90% specificity for miR-
371a-3p, a 70% sensitivity and a 89% specificity for miR-373-
3p and a 79% sensitivity and a 85% specificity for miR-367-
3p. miR-30b levels and the TCam-2 dilution series were used
to compare and normalize the data generated. Data are pre-
sented as 2 (highest dCt in the follow-up series minus dCT). The values
are relative, but linear and high values represent high levels.
3 Results
To assess the value of the ampTSmiR test for the follow-up of
TGCT patients, the miR-371a-3p, miR-373-3p and miR-367-
3p levels were measured in all available serum samples of the
selected patients. For each time point the standard clinical
parameters were available, including the serum biomarkers
B-HCG, AFP and LDH (Supplementary Table 1). The indi-
vidual cases are presented one by one hereunder. The illustra-
tions contain results of the informative serum protein and miR
biomarkers only.
3.1 Case 1
A 34 year old man presented with a mass in the right
testis. The conventional biomarker tests showed elevated
levels of B-HCG (124,603 U/L) (normal range, < 2 U/L),
AFP (722 U/L) (normal range, 0–10 U/L) and LDH
(744 U/L) (normal range < 450 U/L) (Supplementary
Table 1, Fig. 1a-c). The miR-371a-3p, miR-373-3p and
miR-367-3p levels were also found to be elevated at pri-
mary diagnosis (Supplementary Table 1, Fig. 1d-f). The
patient underwent orchidectomy of the affected testis.
Histologically the tumor was composed of a mixed non-
seminoma with EC, YCT, CH, SE, and immature and
mature TE (ITE and MTE). CT imaging revealed enlarged
mediastinal lymph nodes (MLN), left supraclavicular
lymph nodes (LSLN), retroperitoneal lymph nodes
(RPLN) and lung metastases, based on which the patient
was diagnosed with NS stage IV, poor prognosis.
Therefore, he was further treated by initially one cycle
of chemotherapy with vinblastine, ifosfamide and cisplat-
in (VIP), followed by stem cell collection and three addi-
tional cycles of VIP and autologous stem cell treatment.
Five months after the primary diagnosis a residual retro-
peritoneal lymph node was dissected (RPLND). None of
the conventional markers and none of the miRs showed
an elevated level prior to dissection, (Supplementary
Table 1, Fig. 1a-f). Histopathological examination of the
RPLN metastasis after dissection showed large areas of
necrosis and a MTE component. Based on these observa-
tions, the patient received no further treatment and, so far,
the follow-up is without any relapse, consistent with the
non-elevated levels of the conventional and miR bio-
markers. A single elevated level of miR-373-3p was ob-
served 8 months after diagnosis of which the impact is
still unclear. In conclusion, none of the conventional and
miR biomarkers was able to detect the RPLN composed
of TE only.
3.2 Case 2
A 39 old man with a history of orchidopexy at the age of
14 years presented with a mass in his left testis.
Conventional biomarker tests showed elevated levels of B-
HCG (226 U/L) (Fig. 2a, Supplementary Table 1), AFP
(19 U/L) and LDH (2441 U/L) (not shown). The ampTSmiR
test revealed elevated levels of miR-371a-3p, miR-373-3p and
miR-367-3p (Supplementary Table 1, Fig. 2b-e and not
shown). The patient underwent orchidectomy of the affected
testis, and histopathological examination revealed a mixed NS
composed of EC and YST. At the moment of diagnosis CT
imaging revealed the presence of enlarged inguinal lymph
nodes (left) (ILN), RPLN and lung metastases. The patient
was therefore diagnosed as NS stage IV, intermediate risk
group. Further treatment consisted of four cycles of
bleomycin, etoposide and cisplatin (BEP), followed by
RPLND and inguinal LND (left sided). Histopathological ex-
amination of the lymph nodes revealed necrosis and reactive
changes, without viable tumor cells. The B-HCG levels were
found to decrease gradually during the first two months after
surgery and chemotherapy, whereas the AFP, LDH and indi-
vidual miR levels declined rapidly during the first week after
the start of therapy. After 2 months, the miR-371a-3p level
increased and declined again (Fig. 2b). Seven months after
diagnosis the patient developed dysphasia, paresis of the right
arm and seizures. MRI of the brain showed a solitary intracra-
nial metastasis (ICM) located in the left parietal lobe.
Following surgical resection, histopathological examination
revealed a pure EC. The level of B-HCG was found to be
moderately elevated (4.0 U/L) (Supplementary Table 1,
Fig. 2a, arrow), whereas the AFP and LDH levels were normal
(Supplementary Table 1). The miR-371a-3p and miR-373-3p
levels were both found to be elevated at the moment of ICM
detection. The miR-371a-3p levels were increased at least two
months before the brain metastasis was identified (Fig. 2b, c).
In contrast to the serum protein biomarkers, the miR-371a-3p
levels indicated residual disease even before, and possibly
related to, the development of the ICM. After surgery, treat-
ment consisting of radiotherapy of the whole brain and a local
stereotactic boost resulted in a complete clinical remission.
Remarkably, for as yet unknown reasons, positive
ampTSmiR scores were found for miR-371a-3p, miR-373-
3p and miR-367-3p (not shown) at 15 months after relapse.
The patient was lost in follow-up.
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3.3 Case 3
A 21 year old man underwent orchidectomy of the left testis.
Histopathological and clinical examination revealed a pure
SE, stage I. The level of B-HCG at diagnosis was 2.0 U/L
with normal levels of AFP and LDH (Supplementary
Table 1, Fig. 3, AFP data not shown). No serum sample was
available for retrospective miR analysis at the time of primary
diagnosis in this case. The patient was treatead prophylacti-
cally using radiotherapy of the para-aortic lymph nodes
(PAOLN). After 45 months the B-HCG level increased to
2.0 U/L (Fig. 3a), with none-elevated levels of AFP and
LDH (not shown and Fig. 3b). At this time point, an elevated
level of miR-371a-3p was detected (Fig. 3c, red arrow), with
undetectable miR-373-3p and miR-367-3p levels (Fig. 3d and
e). Seven weeks later a para-iliac lymph node (PILN) metas-
tasis was detected by CT imaging. At this time, B-HCG was
modestly elevated (3.3 U/L) as well as the LDH level (473 U/
L), but the AFP level was normal. Concomitantly, all the miR
levels were elevated (Supplementary Table 1, Fig. 3c-e, black
arrow). Because of the relapse, the patient was treated with
three cycles of BEP. Both the protein and the miR biomarker
levels showed a rapid drop after the start of therapy. A com-
plete remission was achieved with a total uneventful follow-
up of 42 months. The patient is still under surveillance. The
levels of both B-HCG and miR-371a-3p, miR-373-3p and
miR-367 indicated the presence of a PILN, of which the first
miR (as well as B-HCG, being borderline) were the first to be
positive. Of interest, at multiple time points positive miR
levels were detected, i.e., absence of reaching an undetectable
level, before the moment of PILN diagnosis. During follow-
up an additional positivity was noted for miR-371a-3p, miR-
373-3p and LDH, all just above the threshold levels, at the
same time point.
3.4 Case 4
A 25 year old man with a history of orchidopexy was treated
for NS stage I by orchidectomy of the right testis.
Histopathological examination revealed a pure EC. At prima-
ry diagnosis the B-HCG level was increased (3.4 U/L, Fig. 4a)
with a normal AFP level and an unknown LDH level
(Supplementary Table 1, and not shown). No serumwas avail-
able for retrospective miR analysis at this time point. The
patient was followed-up by active surveillance. Four years
after diagnosis the B-HCG level was found to be increased
(144 U/L) (Fig. 4a) and a retroperitoneal lymph node metas-
tasis was detected by CT imaging. Retrospective analysis
Fig. 1 Levels of serum markers
at the time of diagnosis, treatment
and follow-up of TGCC case 1. a
The levels of B-HCG (U/L), b
AFP (μg/L), c LDH (U/L), d
miRs-371a-3p, e 373-3p and f
367-3p (relative levels), during
diagnosis at day 0, the time of
orchidectomy (indicated by an
asterisk), follow-up and RPLND
retroperitoneal lymph node
dissection (indicated by an arrow)
are presented. (— cut-off level for
the different markers). Data are
presented as 2 (highest dCt in the
follow-up series minus dCT). The time
of chemotherapywith vinblastine,
ifosfamide and cisplatin (VIP) is
marked by vertical underlined red
lines (I)
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showed that the miR-371a-3p level was elevated at the time of
relapse (Supplementary Table 1 and Fig. 4b, arrow). The miR-
373-3p level was below cut-off level (Fig. 4c). The patient was
treated with three cycles of BEP and a complete remission was
achievedwith a total follow-up of nine years. A single positive
score for miR-373-3p and miR-371a-3p (just above cut-off
level) was obtained seven years after primary diagnosis, but
without known clinical consequences.
3.5 Case 5
A 20 year old man presented with a mass of the right
testis. The patient was diagnosed and treated for SE stage
I by orchidectomy and radiotherapy of the PAOLN
followed by active surveillance. After six years a second
primary tumor was detected in the left testis (30 months
after start of this follow-up series). Histopathological and
clinical examination showed that it was a NS with SE
and EC components, stage IIA. The levels of the conven-
tional biomarkers were normal (Supplementary Table 1).
The miR-371a-3p and miR-373-3p levels were, however,
found to be increased (Fig. 5b and c, red arrow). The
patient was treated with 2 cycles of BEP and 2 cycles
EP. Five months after the second orchidectomy a RPLN
metastasis was detected by CT imaging. The levels of B-
HCG, AFP and LDH were not increased at this time
point (Fig. 5a and not shown), whereas of the different
miRs tested miR-373-3p showed an elevated level just
above the threshold (Fig. 5c, black arrow). During
follow-up two serum samples were found to be miR-
373-3p positive, without known clinical consequences.
As yet, the impact of these observations remains unclear,
but the patient is still under surveillance. The patient was
treated with two cycles of BEP and two cycles of EP. Of
notice, the levels of B-HCG were often found to be in-
creased during follow-up (Fig. 5a), probably due to in-
creased levels of follicle-stimulating hormone caused by
the bilateral orchidectomy [23]. Such a pattern was not
observed for the miRs.
3.6 Case 6
A 22 year old man with a history of orchidopexy of the right
testis at age of 11 years presented with a mass in his left testis.
The conventional biomarker tests showed highly elevated
levels of B-HCG (88,915 U/L), AFP (2024 U/L) and LDH
(3698 U/L) (Fig. 6a-c). Similarly, miR-371a-3p, miR-373-3p
and miR-367-3p showed high levels (Supplementary Table 1,
Fig. 2 Levels of serum markers
at time of diagnosis, of treatment
and follow-up of TGCC case 2. a
The levels of B-HCG (U/L), b
miR-371a-3p, c miR-371a-3p
during the first 12 months of
follow-up, d miR-373-3p, e miR-
373-3p during the first 12 months
of follow-up. The time of
orchidectomy is indicated by an
asterisk. miRs are indicated as
relative levels. Relapse at
7.2 months is indicated by an
arrow. ICM; intracranial
metastasis. (— cut-off level for
the different markers). The time
of chemotherapy with bleomycin,
etoposide and cisplatin (BEP) is
indicated by vertical underlined
blue lines (I) or arrows (c and e)
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Fig. 6d and not shown). The patient underwent orchidectomy
of the affected testis. Histopathological examination showed
that the testis consisted ofMTE and necrosis components (NS,
MTE). CT imaging revealed lung and liver metastases, and
enlarged PAOLN. The patient was, therefore, diagnosed as NS
stage IV with a poor prognosis. The treatment consisted of
four cycles of BEP. After seven months a residual bilateral
RPLND and inguinal LND were performed, as well as orchi-
dectomy of the right testis. Histopathological examination
showed that the RPLN, ILN and testis were all composed of
pure MTE. The levels of B-HCG, AFP and LDH were found
to be normal (Supplementary Table 1, Fig. 6a-c, black arrow).
Based on the clinical data and the levels of the conventional
biomarkers, no further chemotherapy was decided. However,
the patient experienced a late relapse after seven years of fol-
low-up, consisting of lung and RPLN metastases.
Histopathological examination of the LND showed that it
was a NS composed of CH only. The serum biomarkers were
normal and, unfortunately, no serum was preserved for retro-
spectivemiR analysis. The therapy consisted of three cycles of
paclitaxel, ifosfamide and cisplatin (TIP) and radiotherapy,
but no complete remission was achieved. Retrospective revi-
sion of the RPLND at seven months of follow-up indicated
that a CH component was overlooked. In line with this find-
ing, retrospective analysis showed that the miR-371a-3p level
was elevated in four serum samples collected before the oper-
ation (Fig. 6d), providing a strong indication for the presence
of other components than MTE alone.
4 Discussion
Years or even decades after their initial diagnosis, (T)GCC
patients have a risk to develop a second TGCC or a recurrence
of the disease. Therefore, they require intensive and long term
follow-up after diagnosis and treatment [24]. Follow-up strat-
egies differ between centers, but include anamnesis, physical
examination, evaluation of serum tumor markers and repeated
radiological imaging. The basic question addressed in this
proof-of-concept study is whether embryonic miR levels can
predict a relapse of (T)GCC better than the conventional tu-
mor biomarkers B-HCG, AFP or LDH. Although the out-
comes of this study must be validated in, currently ongoing,
independent larger cohorts of patients, the results indicate that
the ampTSmiR test outperforms the conventional biomarkers
in detecting both a primary tumor, residual disease and/or
relapse. For as yet unknown reasons, a few positive results
were observed at time points without recorded clinical events.
This might be related to the sensitivity and specificity thresh-
olds set for this study. These were based on a previous study in
Fig. 3 Levels of serum markers
at time of start of diagnosis of
TGCC case 3. a The levels of B-
HCG (U/L), b LDH (U/L), c
miRs-371a-3p, d 373-3p and e
miR-367-3p (relative levels), at
diagnosis, time of orchidectomy
(indicated by an asterisk), and
during follow-up of this series,
and early relapse detection (red
arrow) are presented. miRs are
indicated as relative levels. 2e p.t.;
second primary tumor, PILN;
para iliac lymph node, indicated
by a black arrow. (— cut-off level
for the different markers). The
time of chemotherapy with BEP
is indicated by vertical underlined
blue lines (I)
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which proven diseased (TGCC) as well as healthy males were
compared [18]. In a clinical setting, a positive miR finding
should therefore be repeated after a week, as is the standard
for conventional serum markers. As of yet, miR analyses
should be performed in addition to conventional serum bio-
marker analyses but, in addition to that, they could already be
very valuable for conventional biomarker negative patients.
In the current series of 6 patients, 5 were found to be pos-
itive based on conventional serum biomarker assays at the time
of primary diagnosis. The actual frequency is, however, lower
in the general population of (T)GCC patients (~60%) [25],
thereby complicating follow-up. Although a relatively small
number of patients is analyzed, a number of conclusions can
be drawn. The miR scores were positive in all four available
cases at primary diagnosis, which is in agreement with the
sensitivity of the ampTSmiR test published before [18, 26],
thereby substantiating the added value of miR profiling at pri-
mary diagnosis. Three out of four cases with a relapse were B-
HCG positive and one case was LDH positive. One case tested
negative for all protein serum biomarkers. The sera of all four
cases were at least positive for one miR, indicating the possible
additional value of the ampTSmiR test for the follow-up of
TGCC patients. Of the three selected miRs, miR-371a-3p
was found to be the most sensitive and specific one and to
Fig. 5 Levels of serum markers at time of diagnosis, treatment and
follow-up of case 5 with a secondary TGCC (red arrow). a The levels
of B-HCG (U/L), b miRs-371a-3p, c 373-3p (relative levels), during
follow-up of this series and relapse (5 months after second
orchidectomy, indicated by a black arrow) are presented. The time of
orchidectomy is indicated by an asterisk. 2e p.t.; second primary tumor,
RPLN; retroperitoneal lymph node. (— cut-off level for the different
markers). Time of chemotherapy with BEP and EP is indicated by
vertical underlined blue lines (I)
Fig. 4 Levels of serum markers at time of diagnosis and follow-up of
TGCC case 4. a The levels of B-HCG (U/L) at diagnosis and follow-up, b
miRs-371a-3p, c 373-3p (relative levels), during follow-up and relapse
are presented. The time of orchidectomy is indicated by an asterisk. The
time of chemotherapy with BEP is indicated by vertical underlined blue
lines (I). RPLN; retroperitoneal lymph node, indicated by an arrow. (—
cut-off level for the different markers)
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outperform the others in detecting a relapse, which is in agree-
ment with recently published results of larger series of patients
with a shorter follow-up and less measure points [19].
Our series includes two patients (no. 1 and 6) with a residual
RPLN after chemotherapy composed of pureMTE. Both cases
showed a normal level of the conventional serum biomarkers,
as expected based on the fact that pure TEs do not secrete HCG
or AFP and do not express embryonic miRs [18, 27]. The
failure to detect pure TE with conventional serum biomarkers
and the ampTSmiR test is of clinical importance since this
chemo-resistant entity requires surgery as treatment to prevent
further progression towards non-germ cell malignancy.
Retrospective analysis of available serum samples revealed
that case no. 6 exhibited increased miR-371a-3p levels in the
period before RPLND, which is indicative for the presence of
other components than TE alone. Indeed, as mentioned above,
histopathological revision of the pathological samples of this
case revealed that the biopsy material contained CH, which
was overlooked at earlier diagnosis. Both observations may
be indicative for additional (chemo)therapy.
The diagnosis of an intracranial germ cell tumor is based on
clinical symptoms, the detection of biomarkers such as AFP and
B-HCG in blood and cerebrospinal fluid, magnetic resonance
imaging of the brain and spinal cord, CSF cytology and histolo-
gy. Here we show that, besides B-HCG, miR-371a-3p and miR-
373-3p are able to predict the presence of an ICM as a TGCT
relapse. This notion indicates that the miRs can pass the blood
brain barrier (BBB) and enter the peripheral blood circulation, in
line with published data [28]. In our case no. 2 the miR-371a-3p
levels were high during VIP therapy, decreased for a month after
therapy and increased again two months before serum protein
biomarker positivity and the detection of ICM, strongly indicat-
ing that no complete remission was achieved.
5 Conclusions
From our data we conclude that the ampTSmiR test is highly
sensitive and specific for the identification of TGCC patients
at primary diagnosis, as well as residual disease and relapse.
The results of this proof-of-concept study warrant further eval-
uation of this molecular biomarker in a larger cohort of pa-
tients with possible active disease during follow-up.
(AFP), α-fetoprotein; (BEP), bleomycin, etoposide and
cisplatin; (B-HCG), human chorionic gonadotropin sub-
unit beta; (CH), choriocarcinoma; (EC), embryonal carci-
noma; (ICM), intracranial metastasis; (LDH), lactate de-
hydrogenase; (miRs), microRNAs; (NS), non-seminoma;
(RPLN), retroperitoneal lymph node; (RPLND), retroper-
itoneal lymph node dissection; (TE), teratoma; (TGCC),
testicular germ cell cancer; (VIP), vinblastine, ifosfamide
and cisplatin; (YST), yolk sac tumor.
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Fig. 6 Levels of serum markers
at time of diagnosis, treatment and
follow-up of TGCC case 6. a The
levels of B-HCG (U/L), b AFP
(μg/L), c LDH (U/L), d miRs-
371a-3p (relative levels), during
diagnosis, follow-up and relapse
are presented. The time of
orchidectomy is indicated by an
asterisk. (— cut-off level for the
different markers). The time of
chemotherapy with BEP is
indicated by vertical underlined
blue lines (I). LND; lymph node
dissections indicated by an arrow
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